



## Objectives

At the end of this session, the attendee will be able to:

- List examples of heterogeneity among fibroid pathology and patient presentations
- Recognize limitations of our current approaches for managing fibroids
- Summarize examples of innovations in diagnosis and therapy in development

3


## Disclosures

- Dr S. Singh has worked with the following industry partners as a consultant, primary investigator (through the Ottawa Hospital Research Institute) and provided CME education lectures:
   Abbvie

  - AllerganBayer
  - Hologic
  - Myovant


4


## Uterine Fibroids & the Pandemic



- Severe bleeding
- Anemia
- Lack of access & delays
- leading to blood


transfusion/urgent surgery







6 7

2021-02-20






)






11 12







13 14









17

Risk Factors

Increased Risks

• Race – Black

• Age

• Premenopausal status

• Hypertension

• Family history

• Time since last birth

• Food additive/soybean milk

Reduced Risk

• OCP or Injectable DMPA (contraception)

• Smoking in low BMI


• pregnancy

• Smoking in low BMI

• pregnancy


| Premenople of State of Operating Systematic Providers

| Smoking in Low BMI
| Pregnancy





19 20



























































41 4





43 44



## Conclusion

- There is significant heterogeneity among fibroids and patient presentations
- One size fits all approach to fibroid care is "behind the times"
- Innovations in diagnosis and Personalized Care should be prioritized

46

45

